Pharma R&D Asia 2014

Featuring Expert Insights

Jun Bao
Senior Vice President & Chief Business Officer, Shenogen Pharma Group, China

Joe Zhang
Executive Deputy Head, Center of Medical and Translation Sciences, Shanghai CP Guojian Pharmaceutical, China

Dr. Narendra Vutla
Executive Vice President & Head of R&D-Wellness, Oral Health & Site Operations, GSK Consumer Healthcare, India

Kantharaj Ethirajulu
Head, Research & Development, Technical- Drug Discovery & Development, The Biomedical Sciences Institute (BMSI), Singapore

Ben Ni
Head & Senior Director, Partnering & External Innovation, Sanofi R&D, China

Peter W. Tsao
Vice President Business Development, TaiGen Biotechnology, Taiwan

Why You Must Attend

- Hear from 25+ R&D Expert Speakers
- Gain Insights on Licensing, M&A, Regulations and More!
- R&D Investment and Funding Opportunities from Leading Venture Capitalists
- Craft IP Strategies and Ensure Formula Confidentiality in the Asian region
- New Interactive and In-Depth Formats: Panel Discussions, Roundtable Discussions, VIP Lunch Tables

Pre-Conference Special Focus Day
26 August 2014 • 9am – 5pm
Clinical Trial Development in Asia

Post Conference Workshop
29 August 2014 • 9am – 5pm
China R&D

Part of:
PharmaCon
Pharmaceutical Congress Asia

Produced by:
ibc Life Sciences
an informa business

Supported by:
Biosingapore

Sponsors:

Media Partners:

International Marketing Partner:

www.pharmaconasia.com
Asia Pharmaceutical Investment Opportunities &
IP Trends & Patent Strategies
Speed Networking
ASEAN harmonization and to what extent will it drive Asian
Introduction to a multi collaboration and partnership model to
Viewpoint of the compulsory licensing system in Asia
Regulatory trends and their impact on R&D investment
Ways to carry out the trials efficiently without compromising on
Collaboration opportunities with venture capitalists
Morning Networking & Refreshment Break
Strategies to minimize and manage these risks
What do these trends signify?
Asia’s Evolving Regulatory Landscape & Development
What are the challenges faced by a global western company when
Chairperson’s Summary of the Day &
Funding models and investment opportunities in Asia
Current regulatory challenges faced and how they can be tackled
Recent pharma marketing regulations changes, expected new
Developing Clinical Trials in Oncology in Singapore
Latest innovations and fields that are gathering interests among
Tackling oncology clinical trials unique risks and managing them
Key criteria for investment
Getting the best out of your partnerships
Laws protecting and ensuring confidentiality when conducting
Advice in clinical trials design for oncology in Singapore
International models, frameworks and standards for Asia to adopt
Singapore’s patent linking system for generics
How regional integration has affected product launch and
What constitutes a good business model and presentation
Current initiatives and regulatory trends in Southeast Asia
Key concerns from the West
Selecting the best business model, communication and operations
Asian Drug Innovation
Strategic Partnerships & Collaboration as a Key to Driving
Jun Bao, Senior Vice President & Chief Business Officer,
Shenogen Pharma Group, China
Billy Sarvanantham Urudr, Chief Commercial Officer,
CCM Pharmaceuticals Sdn Bhd, Malaysia
Dr. Narendra Vutla, Executive Vice President & Head of R&D – Wellness, Oral Health & Site Operations, GSK Consumer Healthcare, India
Carl Firth, CEO, Asia Pharmaceuticals, Singapore
Joy Chen, Director, Regulatory Affairs, Reckitt Benckiser, Singapore
Ariel Valencia, Deputy Director, Food & Drug Administration, Philippines
Koichi Miyazaki, Senior Director, Regulatory Affairs Group, Asia Development Department, Daichii Sankyo, Japan
10:00
Asia’s Evolving Regulatory Landscape & Development
Current initiatives and regulatory trends in Southeast Asia
International models, frameworks and standards for Asia to adopt
Regulatory trends and their impact on R&D investment
Recent pharmacy marketing regulations changes, expected new
guidelines and compliance process under AEC
Are pharmacy companies ready for the implementation and the liberalization of health care services?
Current regulatory challenges faced and how they can be tackled
ASEAN harmonization and to what extent will it drive Asian innovation?
Joy Chen, Director, Regulatory Affairs, Reckitt Benckiser, Singapore
Ariel Valencia, Deputy Director, Food & Drug Administration, Philippines
Koichi Miyazaki, Senior Director, Regulatory Affairs Group, Asia Development Department, Daichii Sankyo, Japan
10:40
Morning Networking & Refreshment Break
Financing, Partnerships & Collaboration
11:25
Chairperson’s Opening Remarks
Jun Bao, Senior Vice President & Chief Business Officer,
Shenogen Pharma Group, China
11:30
Strategic Partnerships & Collaboration as a Key to Driving
Asian Drug Innovation
Introduction to a multi collaboration and partnership model to drive innovation
Getting the best out of your partnerships
Approaches to incorporate partnerships into your R&D model
Ben Ni, Head & Senior Director, Partnering & External Innovation,
Sanofi R&D, China
12:10
Strategic Licensing, Mergers & Acquisitions Trends for
Pharma R&D Development
Evaluating recent licensing and M&A trends in Asia
What do these trends signify?
Different licensing trends for large and small companies, its
challenges and how they can be tackled
Where is the Asian pharmaceutical market headed to?
Yariv Hefez, Vice President Business Development, Portfolio Management, Strategy and Partnering, Biosimilars Unit, Merck Serono, Switzerland
Peter W. Tsao, Vice President Business Development, TaiGen Biotechnology, Taiwan
12:50
Speed Networking
13:00
Networking Lunch
Have a chance to have an informal chat with VIP guests during the networking lunch break
VIP 1: Yuan Hua Ding, Senior Director & Head of External R&D
Innovation – Asia, Pfizer Worldwide Research & Development, Pfizer, USA
VIP 2: Ben Ni, Head & Senior Director, Partnering & External Innovation, Sanofi R&D, China
14:00
Venture Capital Opportunities for Drug Discovery & Development in Asia
Funding models and investment opportunities in Asia
Latest innovations and fields that are gathering interests among venture capitalists
What constitutes a good business model and presentation
Collaboration opportunities with venture capitalists
Key criteria for investment
Goro Takeda, Venture Partner, Sofinova Ventures, Japan
Jun Wu, Chairman & Managing Director, Genova Ventures, China
Jason Mann, Managing Director, Fenex Capital Management, China
14:40
Discovery Outsourcing to Asia: Lessons Learnt
What are the challenges faced by a global western company when outsourcing to Asia?
What were the main challenges faced and how were they tackled?
Advice in clinical trials design for oncology in Singapore
Joanne Chio, Head, Clinical Trials, Haematology-Oncology Research Group, National University Cancer Institute (NCIS), National University Hospital, Singapore
15:50
Managing Risks in Clinical Outsourcing to Southeast Asia
Understanding regulations, clinical infrastructure and risks when conducting clinical trials in Asia
Handling ethnicity and cultural differences within Southeast Asia: What are the differences and similarities in risks?
Strategies to minimize and manage these risks
Establishing standards and IP protection in clinical trials in Southeast Asia
16:30
Developing Clinical Trials in Oncology in Singapore
Difficulties faced in conducting oncology clinical research and how were they tackled
Advise in clinical trials design for oncology in Singapore
Tackling oncology clinical trials unique risks and managing them
Ways to carry out the trials efficiently without compromising on quality and safety
Debolina Partap, Associate Vice President & Head of Legal, Wockhardt Group, India
Soh Kar Liang, Managing Director, Ella Cheong LLC, Singapore
Manh Hung Tran, Principal & Managing Lawyer, BMVN International LLC, a member of Baker & McKenzie International, Vietnam
17:00
IP Trends & Patent Strategies
Insight into compulsory licensing in India and Indonesia
Viewpoint of the compulsory licensing system in Asia
Singapore’s patent linking system for generics
What are the common issues in intellectual property and how can they be addressed?
Laws protecting and ensuring confidentiality when conducting research in Asia
Debolina Partap, Associate Vice President & Head of Legal, Wockhardt Group, India
Soh Kar Liang, Managing Director, Ella Cheong LLC, Singapore
Manh Hung Tran, Principal & Managing Lawyer, BMVN International LLC, a member of Baker & McKenzie International, Vietnam
17:40
Chairperson’s Summary of the Day &
End of Conference Day One
8:30  Morning Networking & Coffee

9:00  Chairperson’s Opening Remarks
Kantharaj Ethirajulu, Head, Research & Development, Technical – Drug Discovery & Development, The Biomedical Sciences Institute (BMSI), Singapore

9:10  Biosimilars & Generics R&D in Asia – What Can We Do To Maintain the Lead?
• Overview of the generics and biosimilars industry in Asia
• A review of science and technology developments for making complex generic drugs
• Strategies in retaining Asia’s stronghold in follow-on drug R&D to ensure Return On Investment (ROI) in sales
• If not follow-on drugs, what’s next?
Moderator
Gene Ching-Hung Hsu, Senior Vice President, HEC Pharm Group, China
Panelists
Kasibhatta Ravisekhar, Vice President, Clinical Research, Lupin Pharmaceuticals, India
Qiang Lu, Chief Scientific Officer, Yangtze River Pharmaceutical Group, China
Joe Zhang, Executive Deputy Head, Center of Medical and Translational Sciences, Shanghai CP Guojian Pharmaceutical, China

9:50  Morning Networking & Refreshment Break

10:20  Biomedical Innovation & Pharmaceutical Growth
• How is pharmaceutical growth in Asia fueling biomedical innovation in the region?
• Potential and current growth areas of focus in Asian biomedical innovation
• Challenges Asia is facing that could limit its growth potential and what can be done
Yuan Hua Ding, Senior Director & Head of External R&D Innovation – Asia, Pfizer Worldwide Research & Development, USA

11:00  Challenges in Drug Discovery & Development in Asia
• Challenges faced in Asia and how to tackle them
• Overcoming lack of fundamental knowledge for drug discovery
• Streamlining drug development process for efficiency
• Drug candidates discovered and developed in Asia
Kantharaj Ethirajulu, Head, Research & Development, Technical – Drug Discovery and Development, The Biomedical Sciences Institute (BMSI), Singapore

11:40  Aggregation in Biosimilars: Orthogonal Analytical Tools in Assessment of Monoclonal Antibodies
• Developing analytical methods to study structural change in biosimilar monoclonal antibodies
• Eliminating structural change due to change in process conditions
• Minimizing structural modifications without compromising on potency of drug
Dr. Kalyan Sundaram, Senior Research Scientist, Lupin, India

12:20  Networking Lunch

13:40  Drug Discovery from Natural Medicines by Novel Approaches
• Post-absorption/metabolism drugs (PAMD) concept
• Discovery of active metabolite in ginseng which is currently in phase III clinical trials for anti-depression
• Results of pharmacokinetics/pharmacodynamics (PK/PD) studies of the metabolite and clinical trials
• Future work and initiatives in areas of natural products drug discovery
William Jia, Chief Scientific Advisor, SAPHRON™ Database Service Centre, Shanghai Innovative Research Centre of Traditional Chinese Medicine (SIRC/TCM), China

14:20  Establishing R&D Infrastructure & Talent Resources
• Current status of clinical and R&D facilities infrastructure
• What are governments in the region doing to improve and promote clinical and R&D development?
• Creating a quality and innovative facility in the Philippines: What is required?
• Current R&D talent pool outlook in the Philippines
• What can be done to further develop, attract and retain R&D talent?
Rodel Sibulo, Director of R&D, Pascual Laboratories, Philippines

15:00  Ensuring Reproducibility during Knowledge & Technology Transfer in R&D Outsourcing
• Determining the right conditions for technology transfer
• Partnering and selecting the right organizations for collaboration
• Advice and methods in ensuring data quality and reproducibility during knowledge transfer
• Getting the maximum benefits out of the collaboration
Qiang Lu, Chief Scientific Officer, Yangtze River Pharmaceutical Group, China

15:40  Afternoon Networking & Refreshment Break

16:20  Roundtable 1: Pharmacokinetics/pharmacodynamics (PK/PD) Guided Clinical Research for Generics
Kasibhatta Ravisekhar, Vice President, Clinical Research, Lupin Pharmaceuticals, India

Roundtable 2: Inhouse vs Outsourced R&D
Hewe Ching Ang, Head of Science Hub, Singapore Region Global External Innovation & Alliances, Bayer Healthcare, Singapore

Roundtable 3: R&D Strategies for an Innovative Pipeline
James Garner, Head, Unit Operations, Sanofi-Aventis, Singapore

17:40  Chairperson’s Closing Remarks & End of the Pharmaceutical R&D Conference
Clinical Trial Development in Asia

This interactive multi-speaker workshop aims to acquaint the participant with the essential skills to develop a quality and regulatory compliant clinical trial in Asia.

8:30 Registration & Morning Coffee

8:50 Introduction
Naeem Noordin, Managing Director, Siara Pte Ltd, Singapore

9:00 Session 1: Clinical Trial Requirements & Regulations in Asia
- Insights into clinical trials requirements and regulations in Asia
- Preparing for a regulatory inspection and tips on what the regulators are looking for
- Crafting and submitting what is required in a clinical trial application (CTA)
Christophe Tournerie, CEO, ClinActs, Singapore

10:30 Morning Networking & Refreshment Break

11:00 Improving & Ensuring the Quality of Clinical Trials & Data
- Quality standards in clinical trials
- Strategies to ensure, monitor and improve clinical trials data quality during outsourcing of clinical trials
- Creating a strategy to minimize risks for data integrity
Emily Tan, Vice President, Clinical Operations Asia Pacific, inVentiv Health Clinical, Singapore

12:30 Networking Lunch Break

13:30 Clinical Site Management & Use of Site Management Organizations (SMO)
- Selection and evaluation of a clinical trial site
- Integration of a quality system, SOPs and training to ensure quality trial data in different clinical sites
- Employing a risk based management to ensure clinical quality at site
- Use of site management organization (SMO)
Shashi Adsul, Head of Clinical Operations, South East Asia, Boehringer-Ingelheim, Singapore

14:00 Application of Digital Technologies for Patient Recruitment & Retention
- Utilizing digital technologies for a patient centric and efficient patient recruitment procedure
- Cutting costs and time through digital recruitment
- Case studies and applications
Ramita Tandon, Senior Vice President & General Manager, inVentiv Health Clinical Trial Recruitment Solutions, USA

15:30 Afternoon Networking & Refreshment Break

16:00 Informed Consent in Clinical Trials
- Informed consent implementation process, guidelines and the people involved
- Systematic development of the informed consent form
- Cultural issues and challenges to be taken into consideration
Naeem Noordin, Managing Director, Siara Pte Ltd, Singapore

17:00 End of Clinical Trial Development in Asia Workshop

China R&D

This workshop aims to introduce you to one of the world’s largest and highly competitive markets – the China R&D market. It will bring you through the important aspects on what is required, the investments, opportunities and key insights on entering and operating in the China R&D market.

8:30 Registration & Morning Coffee

8:50 Introduction

9:00 China Pharmaceutical Market Outlook
- Current pharmaceutical market outlook and progress in China
- Trends and changes in R&D areas of focus in China
- Is it still all about biosimilars in China?

10:00 Morning Networking & Refreshment Break

10:30 Creating Successful Partnerships in China
- Key considerations when partnering with Chinese companies
- Critical advice in getting the most out of your partnership

11:30 R&D Development Models for China
- Crafting a R&D development plan
- How to select a R&D model most suitable for your organization

12:30 Networking Lunch

14:00 Challenges of Selecting and Collaborating with China-Based Preclinical Contract Laboratories
- Selecting pre-clinical contract laboratories in China
- How to access the cost, facilities and labour skills before selecting
- Tips in maintaining confidentiality and ensuring quality in preclinical research

15:00 Afternoon Networking & Refreshment Break

16:00 Integrating Regulatory Concerns with Drug Development in China
- Recent regulatory changes in China
- Overcoming the ever changing regulations during drug development

17:00 End of China R&D Workshop

About Your Workshop Leaders

Gene Ching-Hung Hsu, Senior Vice President, HEC Pharm Group, China
Dr. Hsu is the Senior Vice President at HEC Pharm Group (China). He earned his Ph.D. from Massachusetts Institute of Technology (MIT) and completed his postdoctoral training at University of California at Berkeley. Prior to HEC Pharm, Dr. Hsu was the Chief Scientific Officer and Vice President of Shanghai InnoStar Bio-Tech Co. (China). His professional experience also includes executive and technical positions at TaiGen Biotech Co. (Taiwan), Merck & Co. (USA), and US Federal Government. Dr. Hsu has co-authored over 150 scientific publications, book chapters, and technical reports. He publishes books titled “Clinical Pathology in Experimental Animals” and “Cancer Risk Assessment” (John Wiley & Sons, Inc.). Currently, Dr. Hsu serves on the Editorial Board of two international peer-reviewed journals and is the President-Elect of American Association of Chinese Toxicology (a special interest group of the Society of Toxicology, USA). He is board-certified by the American Board of Toxicology. Dr. Hsu is a recipient of the prestigious “Global Expert Award” by the China Central Government.

Joe Zhang, Executive Deputy Head, Center of Medical and Translational Sciences, Shanghai CP Guojian Pharmaceutical, China
Dr. Zhang joined Shanghai CP Guojian Pharmaceutical Co. Ltd. in February 2014 as the Executive Deputy Head of the Center of Medical and Translational Sciences, overseeing the entire preclinical (GLP tox) and clinical (Phase I to IV) development activities of the company. He also is the architect and a member of the company’s R&D Committee with responsibilities of reviewing and approving key milestones and associated budget for each R&D project. Prior to joining Shanghai CP Guojian, Dr. Zhang served quite a number of roles during his almost 20 years of professional career from scientist to vice president in a variety of organizations including China FDA, Covance, Boehringer-Ingelheim, and Roche. Dr. Zhang is a pharmaceutical industry veteran trained in the United States and China with significant experiences in drug R&D activities. He received his Ph.D. in Toxicology from Indiana University and is a certified toxicologist by American Board of Toxicology. He also has a medical degree and a MPH from Beijing Medical University. Dr. Zhang has been very active in different scientific committees and organizations. He serves as a group leader for RPAC Preclinical Focus Group, a board member for Genetic Toxicology Association (GTA) and American Chinese Society of Toxicology (ACST) and is currently a full member of SOT, GTA, BioSafe, SAPA, and AACC.
IBC Asia's premier Pharma R&D Asia conference aims to facilitate a better understanding of the complex Asian emerging pharmaceutical R&D industry, the opportunities, the challenges and the strategies that senior level decision makers are employing to get the best out of the region. Hear from pharmaceutical R&D experts on the investment opportunities, clinical trial developments, regulatory approval progress, technology transfer, IP protection and more, in this structured learning, networking and value packed four day program. You will no doubt, go home with new business relationships and strategies to successfully grow an innovative R&D pipeline in Asia.

Key Conference Highlights:
- Partnerships and Collaboration Opportunities
- Licensing, M&A Trends in Asia
- Regulatory Trends and Their Impact on your R&D Pipeline
- Market & Investment Opportunities in Asia
- Outsourcing vs Inhouse R&D
- Clinical Trial Requirements & Development
- R&D Strategies for an Innovative Product Pipeline

Who You Will Meet

Part of:
PharmaCon
Pharmaceutical Congress Asia

Showcase Your Research... Present a Poster

If you have new results/data on topics relevant to this conference, we encourage you to submit a poster presentation. Any registered conference attendee may present a poster. Full payment of conference registration and poster fees must be received for the abstract to be included in the conference materials and a poster board assignment to be made (see the registration page for details on the poster fee). Only one poster presentation is allowed per registered attendee/author.

For more information, please email: weifang.sim@ibcasia.com.sg

Sponsorship Opportunities

RAISE awareness of your products and services to regional and international pharmaceutical professionals!
- Stand out from the competition with this branding opportunity
- Meet and develop new client relationships and also affirm existing ones with your presence at this event
- Are you launching new R&D technology or clinical trials services? Now is the time to showcase at this event
- Raise and maintain your corporate profile edge

To check out our tailored sponsorship solutions, please contact: Yvonne Leong, Business Development Manager at Tel: +65 6508 2489 or Email: Yvonne.Leong@ibcasia.com.sg
What is PharmaCon?
The Pharmaceutical Congress Asia (PharmaCon) is the leading annual event that brings together Government, pharmaceutical companies and suppliers in Asia across:

- 4 Conferences
- 10 Workshops
- 4 Days of value-packed information
- Hours of networking opportunities

The dynamic program and networking platform aims to enable companies to develop strong partnerships, drive innovation and growth, as well as winning products and services, in Asia’s growing pharmaceutical industry.

Pharma R&D Asia 2014
Asia’s premier Pharma R&D conference is designed for professionals in the pharmaceutical R&D sector to find out the latest investment, partnership and collaboration opportunities, challenges facing drug discovery and clinical development and how to improve R&D innovation and productivity in Asia.

Who should attend?
Senior level professionals from:
- R&D
- Drug Discovery
- Clinical Trial and Development
- Business Development
- Partnerships & Licensing
- Strategic Alliance Management
- Strategy & Portfolio Management
- Investment
- Mergers & Acquisitions

Who should attend?
Professionals dealing with:
- Global/Regional Regulatory Affairs
- Regulatory Compliance
- Regulatory Submissions & Publishing
- Pharmacovigilance
- Market Access

Who should attend?
- CEO
- Chief Marketing Officer
- President/Managing Director/Vice President of Asia
- Country Manager
- Regional Marketing Director
- Head of Corporate Planning
- Head of Commercialization
- Head of Marketing & Sales
- Head of Market Access
- Head of Business Development
- Head of Multi-Channel Marketing
- Head of Digital Marketing
- Head of Product Development
- Head of Packaging and Labeling
- Head of Procurement & Sourcing
- Head of Compliance

Register today!
+65 6508 2401
register@ibcasia.com.sg
www.pharmaconasia.com
Part of: Pharmacon Pharmaceutical Congress Asia

PHARMA R&D ASIA 2014

4 Successful Events Under 1 Roof
180+ Attendees to Network With
4+ Days of Expert Knowledge Sharing
80+ Expert Pharmaceutical Stakeholders & Key Decision Makers
15+ Interactive Formats to Get To Know Your Peers & Customers
1 Joint Exhibition Area

RESERVE YOUR PLACE TODAY!

Yes! I/We will attend the Pharma R&D Asia 2014 | 26 – 29 August 2014, ParkRoyal Hotel on Beach Road, Singapore
I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.

FEE PER DELEGATE

Early Bird Rate
Special Rate
Normal Rate
Group Rate

4 Day Package: 2 Day Conference + All Workshops
SGD 3,795
SGD 4,095
SGD 4,295
SGD 3,795

3 Day Package: 2 Day Conference
Pre-Conference Workshop OR
Post-Conference Workshop
SGD 3,295
SGD 3,495
SGD 3,695
SGD 3,195

2 Day Conference only
SGD 2,595
SGD 2,795
SGD 2,995
SGD 2,495

Present a Poster
SGD100 for Industry and Free for Academic

GROUP BONUS – Register 3 Delegates from the same company and the 4th Delegate attends FREE!

Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.

Early Bird Rate
Special Rate
Normal Rate

4 Day Package: 2 Day Conference + All Workshops
SGD 3,795
SGD 4,095
SGD 4,295

3 Day Package: 2 Day Conference
Pre-Conference Workshop OR
Post-Conference Workshop
SGD 3,295
SGD 3,495

2 Day Conference only
SGD 2,595
SGD 2,795
SGD 2,995

Delegate 1 Details
Delegate 2 Details
Delegate 3 Details
Delegate 4 Details

Name: Dr/Mr/Ms
Job Title:
Department:
Tel:
Mobile No.:
Email:

Name: Dr/Mr/Ms
Job Title:
Department:
Tel:
Mobile No.:
Email:

Name: Dr/Mr/Ms
Job Title:
Department:
Tel:
Mobile No.:
Email:

Name: Dr/Mr/Ms
Job Title:
Department:
Tel:
Mobile No.:
Email:

Please photocopy for additional delegates

Who is Head of your Department?
Who is Head of Training?

Company Information

Company Name:
Main Business/Activity:
Address:
Postal Code:

Payment Method (Please tick):

I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
I am paying by bank transfer (copy attached)
Payment by Credit Card (AMEX, VISA or MasterCard accepted)

CREDIT CARD PAYMENTS

The best way to pay by credit card is through our secure online registration process, simply log on to the website at www.pharmaconasia.com and click "Register On-Line". If you would prefer to pay over the phone please complete the contact name and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest confidence, please do not send payment details by email.

Credit card contact:
Department:
Direct phone number:
Email:

P46245web

HOTEL INFORMATION

PARKROYAL on Beach Road
7500 Beach Road, Singapore 199591
Hotel mainline: +65 6505 5666
Contact Person: Teo Hui Ling
Tel: +65 6505 5696
Email: teo.huling@parkroyalhotels.com

Bank details:
IBR Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:020-457866-176 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGG
Bank Code: 7323

CANCELLATIONS / SUBSTITUTION

Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.

IMPORTANT NOTE

Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6505 2407). Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC assumes no further liability or obligation, beyond the refund of the paid registration fee, in the event of postponement or cancellation by IBC.

DATA PROTECTION

The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Occasionally, your details may be obtained from or shared with external companies who wish to communicate with you offers related to your business activities. If you do not wish your details to be used for this purpose, please contact our Database Department at Email: database@ibcasia.com.sg, Tel: +65 6505 2400 or Fax: +65 6505 2407.

SAVE WITH THE EARLY BIRD & SPECIAL RATES!

ENJOY SUBSTANTIAL SAVINGS WITH OUR MULTIPLE BOOKING DISCOUNT!

6 EASY WAYS TO REGISTER

MAIL the attached registration form with your cheque to IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset
#10-06, Singapore 238164
Customer Service Hotline
+65 6508 2401
Email
register@ibcasia.com.sg

_SCAN THE QR CODE WITH YOUR SMART PHONE TO PAY BY PHONE OR REGISTER NOW!

Search "IBC Asia" to find us on Facebook & LinkedIn

Hotel mainline: +65 6505 5666
Contact Person: Teo Hui Ling
Tel: +65 6505 5696
Email: teo.huling@parkroyalhotels.com

Fax
+65 6508 2407
Web
www.pharmaconasia.com

REG NO. 200108203N